News

Deals & Cases

Financing Round of CRISPR Therapeutics

19 May 2015 – CRISPR Therapeutics conducted a Series A financing of CRISPR Therapeutics. CRISPR Therapeutics is a biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology into transformative medicines. The financing round is led by SR One and includes new investors New Enterprise Associates (NEA) and Abingworth, alongside the founding investor, Versant Ventures.

Walder Wyss AG, led by Alexander Gutmans (Partner, Corporate/M&A), advises the investors on the Swiss law aspects together with Wilson Sonsini Goodrich & Rosati as Lead Counsel.

Technically necessary cookies

Essential technical cookies are necessary for the flawless functioning of our website and cannot be disabled.
Cookies for statistics

Analytical cookies enable us to count visits and traffic sources, allowing us to measure and enhance the performance of our website. They assist us in answering questions such as which pages are the most popular, which are the least used, and how visitors navigate the website. All information collected by these cookies is aggregated and therefore anonymous.
Marketing cookies may be set by our advertising partners on our website. These companies can use them to create a profile of your interests and display relevant advertisements on other websites. They operate by uniquely identifying your browser and device. By activating these cookies, you acknowledge and consent to the information collected by such cookies being sent to providers outside of Switzerland and the EU, including countries with (from the perspective of Swiss data protection law) inadequate data protection (e.g., the United States, Singapore, and Taiwan). You also acknowledge that data transmitted abroad is no longer protected by Swiss law, and foreign laws as well as regulatory orders may require the disclosure of this data to authorities and other third parties.

Marketing cookies may be set by our advertising partners on our website. These companies can use them to create a profile of your interests and display relevant advertisements on other websites. They operate by uniquely identifying your browser and device. By activating these cookies, you acknowledge and consent to the information collected by such cookies being sent to providers outside of Switzerland and the EU, including countries with (from the perspective of Swiss data protection law) inadequate data protection (e.g., the United States, Singapore, and Taiwan). You also acknowledge that data transmitted abroad is no longer protected by Swiss law, and foreign laws as well as regulatory orders may require the disclosure of this data to authorities and other third parties.

News

Financing Round of CRISPR Therapeutics

We use cookies